tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
ArriVent Biopharma resumed with a Buy at Goldman Sachs
PremiumThe FlyArriVent Biopharma resumed with a Buy at Goldman Sachs
14d ago
Premium
Company Announcements
ArriVent BioPharma Announces $75 Million Public Offering
21d ago
ArriVent Biopharma 2.5M share Spot Secondary priced at $19.50
Premium
The Fly
ArriVent Biopharma 2.5M share Spot Secondary priced at $19.50
22d ago
PremiumRatingsArriVent BioPharma’s Firmonertinib Shows Promise in NSCLC Treatment with Strong Phase 1b Results and Strategic Phase 3 Plans
1M ago
Premium
Ratings
Promising Prospects for ArriVent BioPharma: Buy Rating Affirmed Amidst Positive Clinical Data and Increased Target Price
1M ago
Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’
Premium
The Fly
Citi ups ArriVent price target to $40, adding ‘upside 90-day short-term view’
1M ago
PremiumRatingsPromising Outlook for ArriVent BioPharma: Buy Rating Justified by Upcoming EGFR PACC Mutant NSCLC Program Updates
2M ago
ArriVent Biopharma initiated with a Buy at JonesResearch
Premium
The Fly
ArriVent Biopharma initiated with a Buy at JonesResearch
2M ago
ArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
Premium
The Fly
ArriVent Biopharma price target raised to $40 from $39 at H.C. Wainwright
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100